Document Detail


Von Willebrand factor and fibrinolytic parameters during the desmopressin test in patients with Cushing's disease.
MedLine Citation:
PMID:  21143510     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Desmopressin is a known haemostatic agent and is also being used, albeit at lower doses, during the diagnostic work-up of Cushing's syndrome, a condition characterized by excess cortisol concentrations and frequent thromboembolic events. No study has yet evaluated whether administration of desmopressin for diagnostic purposes induces significant, adverse changes in endothelial cell markers in these patients.
WHAT THIS STUDY ADDS: Administration of desmopressin to patients with Cushing's disease induces changes in endothelial cell markers comparable with those observed in obese and normal weight subjects. It follows, that desmopressin testing does not induce disease-specific untoward changes in coagulatory markers in patients with endogenous hypercortisolism and its use in this context appears safe.
AIMS: Desmopressin, a vasopressin analogue, is used for various clinical purposes, including haemostasis and, in recent times, the diagnostic work-up of patients with Cushing's syndrome, a condition associated with a known prothrombotic profile. We decided to evaluate whether and to what extent a diagnostic dose of desmopressin induces significant changes in endothelial parameters in patients with Cushing's disease (CD) and obese and normal weight controls.
METHODS: Twelve patients with CD, 10 obese and five normal weight controls were studied. Von Willebrand antigen (VWF:Ag), tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) were measured at baseline and up to 4 h after 10 µg desmopressin i.v.
RESULTS: Desmopressin 10 µg transiently increased VWF:Ag and t-PA and decreased PAI-1 in all subjects. The magnitude of the VWF:Ag and t-PA increases after desmopressin was comparable in the three groups (VWF:Ag peak-to-basal ratio 1.9 ± 0.17, 1.5 ± 0.11 and 1.8 ± 0.13 and t-PA peak-to-basal ratio 1.6 ± 0.18, 1.6 ± 0.20 and 1.8 ± 0.24 for CD, obese and controls, respectively, all NS). The PAI-1 decrease observed in patients with CD was comparable with obese (0.7 ± 0.07 and 0.6 ± 0.09, NS) and controls (0.7 ± 0.07 vs. 0.4 ± 0.09, P= 0.08).
CONCLUSIONS: Administration of desmopressin to patients with CD for diagnostic purposes induces a transitory increase in VWF:Ag counterbalanced by a decrease in PAI-1 and increase in t-PA. The magnitude of these changes is largely comparable with that observed in obese and normal weight controls. Our data show that testing with desmopressin does not induce disease-specific changes in endothelial markers in patients with CD.
Authors:
Francesca Pecori Giraldi; Alberto G Ambrogio; Letizia M Fatti; Valentina Rubini; Giovanna Cozzi; Massimo Scacchi; Augusto B Federici; Francesco Cavagnini
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  71     ISSN:  1365-2125     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-14     Completed Date:  2011-02-24     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  132-6     Citation Subset:  IM    
Copyright Information:
© 2010 The Authors. British Journal of Clinical Pharmacology © 2010 The British Pharmacological Society.
Affiliation:
Cattedra di Endocrinologia, Università di Milano, Ospedale San Luca, Istituto Auxologico Italiano IRCCS, Piazzale Brescia 20, Milan, Italy. fpg@auxologico.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Body Weight
Case-Control Studies
Deamino Arginine Vasopressin / diagnostic use*
Fibrinolysis / drug effects*
Humans
Pituitary ACTH Hypersecretion / blood,  diagnosis*
Plasminogen Activator Inhibitor 1 / metabolism*
Tissue Plasminogen Activator / metabolism*
von Willebrand Factor / immunology*,  metabolism
Chemical
Reg. No./Substance:
0/Plasminogen Activator Inhibitor 1; 0/Von Willebrand antigen; 0/von Willebrand Factor; 16679-58-6/Deamino Arginine Vasopressin; EC 3.4.21.68/Tissue Plasminogen Activator
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Proof of concept study to evaluate step-down therapy with inhaled corticosteroid alone or additive t...
Next Document:  Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of curre...